New evidence suggests that SARS-CoV-2 infection can lead to the rapid development of achalasia, a rare esophageal motility disorder. The etiology of achalasia is unclear. Studies have suggested an ...

Among the participants who tested positive for SARS-CoV-2 infection, 475 developed T1D during the post-acute period, with an incidence rate of 90.5 (95% CI, 82.7-99.0) per 100,000 person-years ...

With climate change bringing more frequent and severe heat waves to much of the U.S. and the world, people will likely be spending even more time indoors in summertime—and so will SARS-CoV-2.

We used health records of the Department of Veterans Affairs to build a study population of 441,583 veterans with SARS-CoV-2 infection between March 1, 2020, and January 31, 2022, and 4,748,504 ...

UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...

Nirmatrelvir is a potent, selective SARS-CoV-2 main protease inhibitor. 18,19 The Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients (EPIC-HR) trial involving patients at high ...